Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content
Springer Nature Link
Log in

Aspirin use and prostate tumor angiogenesis

  • Short Communication
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

Aspirin use has been shown to be associated with reduced risk of aggressive prostate cancer, although the mechanisms are not fully understood.

Methods

We examined associations between regular aspirin use and prostate tumor angiogenesis among 572 men from the Health Professionals Follow-up Study. Participants reported aspirin use on biennial questionnaires. Prostatectomy tumor blocks were immunostained for CD34 to assess microvessel size and irregularity. Multivariable linear regression was used to calculate percent differences in biomarker measures comparing use vs nonuse, and by duration and tablets per day.

Results

Current aspirin users had larger vessel area (14.5%) and diameter (6.5%), and lower vessel irregularity (− 8.1%) compared to non-users, indicating a less angiogenic profile. Duration of use and current tablets per day were also associated with larger vessel diameter. Similar patterns were seen for low- and high-grade prostate cancers.

Conclusion

Our findings suggest that aspirin use, particularly current use, can lower prostate cancer carcinogenesis through angiogenic mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from £29.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

Data availability

Information regarding procedures for obtaining and accessing HPFS data are described at https://sites.sph.harvard.edu/hpfs/for-collaborators/.

References

  1. Mucci LA, Powolny A, Giovannucci E et al (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27(33):5627–5633

    Article  Google Scholar 

  2. Liu Y, Chen JQ, Xie L et al (2014) Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 12:55

    Article  CAS  Google Scholar 

  3. Downer MK, Allard CB, Preston MA et al (2019) Aspirin use and lethal prostate cancer in the health professionals follow-up study. Eur Urol Oncol 2(2):126–134

    Article  Google Scholar 

  4. Gupta S, Adhami VM, Subbarayan M et al (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64(9):3334–3343

    Article  CAS  Google Scholar 

  5. Liu XH, Kirschenbaum A, Yao S et al (2000) Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164(3 Pt 1):820–825

    Article  CAS  Google Scholar 

  6. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1(1):11–21

    Article  CAS  Google Scholar 

  7. Pathi S, Jutooru I, Chadalapaka G et al (2012) Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors. PLoS One 7(10):e48208

    Article  CAS  Google Scholar 

  8. Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank the participants and staff of the Health Professionals Follow-up Study for their valuable contributions, as well as the following US state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The authors assume full responsibility for analyses and interpretation of these data.

Funding

This work was supported by grants from the National Institutes of Health (Grant Numbers U01 CA167552, T32 CA009001) and the American Institute for Cancer Research.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA

    Benjamin C. Fu, Kai Wang, Lorelei A. Mucci & Edward L. Giovannucci

  2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

    Lorelei A. Mucci & Edward L. Giovannucci

  3. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA

    Steven K. Clinton

  4. The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA

    Steven K. Clinton

  5. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Edward L. Giovannucci

Authors
  1. Benjamin C. Fu
    View author publications

    Search author on:PubMed Google Scholar

  2. Kai Wang
    View author publications

    Search author on:PubMed Google Scholar

  3. Lorelei A. Mucci
    View author publications

    Search author on:PubMed Google Scholar

  4. Steven K. Clinton
    View author publications

    Search author on:PubMed Google Scholar

  5. Edward L. Giovannucci
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Drs. Fu and Giovannucci had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Fu, Giovannucci. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: Fu. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Fu. Obtained funding: Mucci, Giovannucci. Supervision: Giovannucci.

Corresponding author

Correspondence to Benjamin C. Fu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, B.C., Wang, K., Mucci, L.A. et al. Aspirin use and prostate tumor angiogenesis. Cancer Causes Control 33, 149–151 (2022). https://doi.org/10.1007/s10552-021-01501-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1007/s10552-021-01501-6

Keywords